良性前列腺增生手术治疗后延长下尿路症状药物使用:美国医疗索赔分析
基于美国医保与商业保险索赔随机样本,分析因良性前列腺增生接受经尿道前列腺电切术、绿激光前列腺汽化术或前列腺尿道提升术的患者术后持续及新发使用α受体阻滞剂、5α还原酶抑制剂或联合药物治疗的比例。术后1年用药率前列腺尿道提升术最低(4.1%),低于经尿道前列腺电切术(6.2%)和绿激光前列腺汽化术(6.6%);至5年时三种术式用药率相近(经尿道前列腺电切术10.6%、绿激光前列腺汽化术10.4%、前列腺尿道提升术10.3%)。
要点
- 术后1年用药率前列腺尿道提升术4.1%,低于经尿道前列腺电切术6.2%和绿激光前列腺汽化术6.6%。
- 术后5年用药率三种术式相近:经尿道前列腺电切术10.6%、绿激光前列腺汽化术10.4%、前列腺尿道提升术10.3%。
- 无论何种术式,约10%患者术后5年内仍使用良性前列腺增生药物。
核心结论
- 接受良性前列腺增生手术的患者可能希望停用或绕过药物,但数据显示约10%患者术后5年内仍使用药物,与所行术式无关。
研究设计与样本
- 基于美国医保与商业保险索赔随机代表性样本的医疗索赔分析,纳入有至少1年随访数据的门诊经尿道前列腺电切术、绿激光前列腺汽化术或前列腺尿道提升术患者,并链接药品索赔以评估持续及新发用药率。
主要发现
- 共36629例确诊良性前列腺增生的男性接受门诊手术:经尿道前列腺电切术20319例、绿激光前列腺汽化术10517例、前列腺尿道提升术5793例。
- 术后1年用药率前列腺尿道提升术4.1%,低于经尿道前列腺电切术6.2%和绿激光前列腺汽化术6.6%。
- 术后5年用药率经尿道前列腺电切术10.6%、绿激光前列腺汽化术10.4%、前列腺尿道提升术10.3%,三种术式间相当。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative medication use is an important yet relatively unexplored element of the benign prostatic hyperplasia patient journey. We assessed and compared the percentage of patients who required medication postoperatively after the three most common BPH surgeries in the real world: transurethral resection of the prostate (TURP), photovaporization procedure with GreenLight Laser (PVP), and prostatic urethral lift (PUL) with the UroLift system. METHODS: Within a random representative sample of US Medicare and commercial insurance claims, patients with at least one year of follow-up data available after an outpatient TURP, PVP, or PUL procedure were linked to pharmaceutical claims to elucidate rates of continuous and de novo use of alpha-blockers, 5-alpha reductase inhibitors, or combination medical therapy. Periods of interest were perioperative (use within three months postoperatively and not beyond) and one and five years postoperatively. RESULTS: 36 629 men diagnosed with BPH underwent outpatient TURP (n = 20 319), GreenLight PVP (n = 10 517) and PUL (n = 5 793) procedures within the claims dataset. The rate of medical therapy use through one year was lowest for PUL (4.1%) compared to TURP (6.2%) and PVP (6.6%), and was equivalent between procedures through five years (10.6% TURP, 10.4% PVP, and 10.3% PUL). CONCLUSIONS: Patients who undergo surgery to treat BPH may desire to discontinue or bypass BPH medications. However, these data demonstrated that approximately 10% of BPH patients used medication through five years postoperatively, regardless of which procedure they underwent.
引用
- Kaplan S, Kaufman RP, Elterman D, et al. Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis. Prostate Cancer Prostatic Dis. 2025. PMID: 40016360. doi:10.1038/s41391-025-00953-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。